Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
[Kaposi's sarcoma]
Gan To Kagaku Ryoho. 1985 Sep;12(9):1749-54. Unique Identifier : AIDSLINE MED/85305777 Hayasaka K; Ishihara K
Abstract:
Kaposi's sarcoma (KS) is a very rare disease in Japan. The description by Moritz kaposi in 1872 of a multiple idiopathic pigment sarcoma of the skin stressed the multifocal lesions of the disease and its vascular nature, and it was renamed multiple idiopathic hemorrhagic sarcoma. For many years, the traditional form of KS was seen by most dermatologists and pathologists. During the 1970s, following the initiation of immunosuppression therapy for kidney transplantation, on autoimmune disease, KS was observed to occur in up to 5% of patients undergoing this procedure. In 1981, reports began to appear of kaposi's sarcoma in young immunocompromised homosexual men. Many patients bad lymphadenopathy and/or unusual opportunistic infections. The clinical manifestations of traditional KS were and are well established. The initial lesions usually involve the lower extremities, beginning as macules and patches and extending to plaques and modules. The color is thought to be somewhat distinctive, especially in the later stages, with hues of red or red-brown with a bluish purple tone. Eventually, non-pitting edema of the legs is seen, with widely scattered involvement of cutaneous lymph nodes and eventually, internal organs. The disease is considered to be multifocal both in the traditional and AIDS-associated (new KS) forms. The clinical course of the disease is variable. The differential diagnosis of KS has become a major problem in histopathology. Factor-VIII-related antigen may be demonstrated in vascular endothelium using immunoperoxidase staining methods and may be useful, as a practical approach to skin biopsy in high-risk patients, awareness of the differential diagnoses is of primary importance. An abnormal helper: suppressor ratio of T lymphocytes is found in most of the immunocompromised groups, KS patients are treated by radiation and/or chemotherapy. Some drugs are well-suited for the long-term treatment of KS.
Keywords: Antineoplastic Agents, Combined/THERAPEUTIC USE Biopsy Combined Modality Therapy Diagnosis, Differential English Abstract Hodgkin's Disease/DIAGNOSIS Human Lymphoma, Non-Hodgkin's/DIAGNOSIS Radiotherapy Dosage Sarcoma, Kaposi's/*DIAGNOSIS/PATHOLOGY/THERAPY Skin/PATHOLOGY Skin Neoplasms/*DIAGNOSIS/PATHOLOGY/THERAPY JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
